Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Dow
McKesson
Baxter
Colorcon

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRABECTEDIN

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Trabectedin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002904 Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 1 1996-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of ecteinascidin 743 in treating adults with advanced solid tumors.
NCT00003939 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 2 1969-12-31 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have advanced soft tissue sarcoma.
NCT00005625 Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma Completed National Cancer Institute (NCI) Phase 2 1999-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have previously treated metastatic osteosarcoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Trabectedin

Condition Name

Condition Name for Trabectedin
Intervention Trials
Sarcoma 11
Soft Tissue Sarcoma 9
Leiomyosarcoma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Trabectedin
Intervention Trials
Sarcoma 35
Ovarian Neoplasms 13
Leiomyosarcoma 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Trabectedin

Trials by Country

Trials by Country for Trabectedin
Location Trials
United States 249
Italy 114
Spain 26
Germany 19
France 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Trabectedin
Location Trials
New York 14
California 13
Massachusetts 13
Pennsylvania 12
Washington 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Trabectedin

Clinical Trial Phase

Clinical Trial Phase for Trabectedin
Clinical Trial Phase Trials
Phase 3 13
Phase 2/Phase 3 1
Phase 2 39
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Trabectedin
Clinical Trial Phase Trials
Completed 28
Recruiting 26
Not yet recruiting 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Trabectedin

Sponsor Name

Sponsor Name for Trabectedin
Sponsor Trials
PharmaMar 32
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 12
National Cancer Institute (NCI) 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Trabectedin
Sponsor Trials
Other 73
Industry 68
NIH 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Dow
AstraZeneca
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.